Recurrent erysipelas: 47 cases.

Recurrence is a common complication of erysipelas (cellulitis).
Todescribe the characteristics of patients with recurrent erysipelas and thereby, identify potential risk factors and evaluate prophylaxis efficacy.
Data were retrospectively recorded from the files of 47 patients admitted to hospital between 1995 and 2003 for erysipelas recurrence. Studied variables included: general condition, regional and local factors, e.g. broken cutaneous barrier. Patient characteristics were used to construct tree-based models according to the classification and regression tree methodology.
Our patients suffered a mean of 4.1 recurrences. Cutaneous barrier disruption was observed in 81%, mainly intertrigo (60%). Antibiotic prophylaxis was taken by 68% of the patients for 30.6 months. After 1 and 2 years, 84 and 72% of the patients, respectively, were recurrence-free.
Our results showed that erysipelas recurrence has the same risk factors as single episodes and underlines the potential benefit of oral or parenteral antibiotic prophylaxis to prevent recurrences.
AuthorsS Leclerc, A Teixeira, E Mahé, V Descamps, B Crickx, O Chosidow
JournalDermatology (Basel, Switzerland) (Dermatology) Vol. 214 Issue 1 Pg. 52-7 ( 2007) ISSN: 1018-8665 [Print] Switzerland
PMID17191048 (Publication Type: Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents (therapeutic use)
  • Antibiotic Prophylaxis (methods)
  • Erysipelas (diagnosis, drug therapy, epidemiology)
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Secondary Prevention

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: